Investing.com - Taro Pharma Industries (NYSE: TARO) reported fourth quarter EPS of $0.40, $0.09 better than the analyst estimate of $0.31. Revenue for the quarter came in at $164.9M versus the consensus estimate of $156.06M.
Taro Pharma Industries's stock price closed at $42.43. It is up 0.71% in the last 3 months and up 43.88% in the last 12 months.
Taro Pharma Industries saw 0 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Taro Pharma Industries's stock price’s past reactions to earnings here.
According to InvestingPro, Taro Pharma Industries's Financial Health score is "great performance".
Check out Taro Pharma Industries's recent earnings performance, and Taro Pharma Industries's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar